Comparative Pharmacology
Head-to-head clinical analysis: ADLARITY versus PYRIDOSTIGMINE BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLARITY versus PYRIDOSTIGMINE BROMIDE.
ADLARITY vs PYRIDOSTIGMINE BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADLARITY is a transdermal formulation of donepezil, a reversible acetylcholinesterase inhibitor that increases acetylcholine levels in the central nervous system, improving cholinergic neurotransmission in the cerebral cortex.
Reversible acetylcholinesterase inhibitor, prolonging the action of acetylcholine at nicotinic and muscarinic receptors.
10 mg transdermal patch applied once daily to clean, dry, hairless skin on the back, chest, or upper arm.
Oral: 60-120 mg every 3-4 hours (max 360 mg/day). Intravenous: 0.1-0.25 mg/kg IV (max 10 mg per dose) for reversal of nondepolarizing neuromuscular blockade, given with glycopyrrolate or atropine. Intramuscular: 0.2-1 mg for postoperative urinary retention.
None Documented
None Documented
Terminal half-life approximately 70 hours (range 50-100 hours); steady-state achieved within 14-21 days; once-daily dosing due to long half-life.
Terminal half-life: 1-2 hours (prolonged in renal impairment; up to 6 hours in anuria)
Renal: ~60% as unchanged donepezil and metabolites (primarily donepezil, 6-O-desmethyl donepezil, and donepezil-N-oxide); fecal: ~15-20% (biliary excretion of metabolites); minor via urine as conjugates.
Renal: 70-90% unchanged; biliary/fecal: minor (<10%)
Category C
Category A/B
Cholinesterase Inhibitor
Cholinesterase Inhibitor